after joining the study you will be randomly assigned to receive either kite-753 or axicabtagene ciloleucel. the assignment is made by the study team and cannot be chosen.

before the medication is given you will undergo baseline tests that may include blood work, imaging scans and other examinations. these assessments confirm that you meet the study criteria and provide a reference point for later comparisons.

the assigned medication is delivered as an intravenous infusion, meaning the drug is slowly administered through a vein. the specific dose is defined by the study protocol but is not disclosed in the public information. the infusion is given once.

after the infusion you will be observed for a period of time in the clinic or hospital. health professionals will watch for any immediate side effects and will perform basic checks such as vital signs and blood tests.

you will return for regular study visits. during these visits the study team will repeat blood tests, imaging examinations (for example, PET‑CT scans) and other evaluations to check how the disease is responding and to monitor safety.

at month 6 after the infusion a formal assessment is performed to determine complete response (CR). complete response means that no evidence of disease is found based on imaging and clinical criteria. this assessment is a primary goal of the study.

throughout the remainder of the study you will continue to be evaluated for any signs of disease progression, survival status and possible adverse events. these evaluations may occur at additional time points defined by the study protocol.

the study continues until the planned end date of the trial, which is estimated to be 2031‑05‑30. at the final visit the study team will collect all remaining data, including long‑term outcomes and quality‑of‑life questionnaires.